Adlai Nortye Ltd.
IPOAdlai Nortye
- Website
- adlainortye.com
- Total Funding
- $253.0M
- Last Round
- $100.0M Series DJul 2021
- Rounds
- 3
- Type
- Public
About
Global clinical-stage biopharmaceutical company developing differentiated immuno-oncology medicines, listed on Nasdaq under ticker ANL.
Summary
Adlai Nortye Ltd. is a healthtech company. It has raised $253.0M in total across 3 rounds, most recently a $100.0M Series D round in Jul 2021. Investors include Cormorant Asset Management, SDIC Fund Management and Matrix Partners China.
Tech & App Stack
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingSign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Feb 2026
Sign up to see all 5 rounds
Full funding history, per-round amounts, and investor participation.
Create Free AccountInvestors
Similar Companies
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
World-leading Canadian cannabis company cultivating and selling medicinal and recreational cannab...
Specialty pharmaceutical company
Biopharmaceutical services company
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...